StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $1.87 | $1.80 | -3.74% | 0.2M |
| 05-14 | $1.81 | $1.78 | -1.66% | 0.4M |
| 05-15 | $1.71 | $1.70 | -0.58% | 0.3M |
| 05-18 | $1.68 | $1.66 | -1.19% | 0.2M |
| 05-19 | $1.65 | $1.66 | +0.61% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for AIFF.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. The firm is developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The company has one reportable segment: the BNA platform. The Company derives revenue from North America.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $485.00K | $1.14M | $730.00K | $342.00K |
Operating Income | $-2.01M | $-8.86M | $-6.36M | $-3.70M |
Net Income | $-2.00M | $-19.88M | $-17.40M | $-1.83M |
EPS (Diluted) | $-0.13 | $-1.97 | $-1.81 | $-1.69 |
Total Assets | $10.91M | $10.48M | $12.41M | $14.94M |
Total Liabilities | $2.47M | $2.84M | $2.75M | $2.84M |
Cash & Equivalents | $3.13M | $2.75M | $4.33M | $5.92M |
Free Cash Flow OCF − CapEx | $-2.01M | $-8.32M | $-6.49M | $-4.92M |
Shares Outstanding | 14.87M | 13.96M | 13.48M | 13.30M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.